Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €53B | 13.7x | 1.31 | €490 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €53B | 13.7x | 1.31 | €488 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €40.88B | 58x | €577.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €31.97B | 42.8x | 0.12 | €524.20 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €31.97B | 42.8x | 0.12 | €521 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €31.97B | 42.8x | 0.12 | €521.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €31.97B | 42.8x | 0.12 | €521.40 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €22.31B | 19.8x | 6.81 | €128.35 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €20.84B | -31.2x | 0.18 | €85.55 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €20.84B | -31.2x | 0.18 | €86.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €20.84B | -31.2x | 0.18 | €85.35 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €10.97B | 10.5x | 0.12 | €173.90 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €10.97B | 10.5x | 0.11 | €172.56 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Paris | Healthcare | Biotechnology & Medical Research | €9.55B | 33.3x | 0.61 | €49.57 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Eurofins Scientific | BATS Europe | Healthcare | Biotechnology & Medical Research | €9.03B | 33.3x | 0.62 | €49.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €9.03B | 33.3x | 0.61 | €49.70 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Frankfurt | Healthcare | Biotechnology & Medical Research | €9.03B | 33.3x | 0.61 | €49.14 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.91B | 20.1x | 0.1 | €31.66 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.69B | -22.1x | -0.89 | €140 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Xetra | Healthcare | Biotechnology & Medical Research | €8.40B | -3.8x | -0.11 | €21.90 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | €8.40B | -3.8x | -0.11 | €21.95 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.40B | -3.8x | -0.11 | €21.83 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €8.40B | -3.8x | -0.11 | €21.94 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €7.74B | 104.5x | -1.43 | €35.92 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €7.74B | 104.5x | -1.43 | €35.93 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €7.74B | 104.5x | -1.44 | €35.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €7.74B | 104.5x | -1.43 | €35.98 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.4% Upside | Upgrade to Pro+ | |
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €7.74B | 104.5x | -1.42 | €35.73 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €4.76B | -88x | -0.88 | €71.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.97B | -10.6x | 0.52 | €24.91 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.62B | -13.7x | 1.15 | €34.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.63B | -6.4x | 0.03 | €11.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €1.56B | 19.3x | 0.14 | €28.65 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.56B | 19.3x | 0.14 | €28.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.56B | 19.3x | 0.14 | €28.53 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.44B | -1,163x | 16.72 | €21.70 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.44B | -1,163x | 16.72 | €21.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | €1.44B | -1,163x | 16.72 | €21.84 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ | |
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.24B | -307.8x | 2.36 | €18.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.23B | -307.8x | 2.35 | €18.84 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.14B | -5.8x | 0.07 | €6.33 | 8.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.14B | -5.8x | 0.07 | €6.24 | 7.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.14B | -5.8x | 0.07 | €6.37 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.14B | -5.8x | 0.07 | €6.40 | 9.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.14B | -5.8x | 0.07 | €6.47 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €940.76M | -5.2x | -0.22 | €11.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Iovance Biotherapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €882.20M | -3.3x | -0.09 | €2.71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Syndax Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €872.90M | -3.9x | 0.12 | €9.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CareDx | Frankfurt | Healthcare | Biotechnology & Medical Research | €858.73M | 17.6x | 0.16 | €16.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €848.58M | -6.4x | -0.07 | €5.20 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |